Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 12/2009

01-12-2009 | Guidelines

EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2

Authors: Andrea Varrone, Susanne Asenbaum, Thierry Vander Borght, Jan Booij, Flavio Nobili, Kjell Någren, Jacques Darcourt, Özlem L. Kapucu, Klaus Tatsch, Peter Bartenstein, Koen Van Laere

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 12/2009

Login to get access

Abstract

These guidelines summarize the current views of the European Association of Nuclear Medicine Neuroimaging Committee (ENC). The purpose of the guidelines is to assist nuclear medicine practitioners in making recommendations, performing, interpreting, and reporting the results of fluorine-18 fluoro-2-deoxyglucose ([18F]FDG) PET imaging of the brain. The aim is to help achieve a high standard of FDG imaging, which will increase the diagnostic impact of this technique in neurological and psychiatric practice. The present document replaces a former version of the guidelines that were published in 2002 [1] and includes an update in the light of advances in PET technology, the introduction of hybrid PET/CT systems and the broadening clinical indications for FDG brain imaging. These guidelines are intended to present information specifically adapted for European practice. The information provided should be taken in the context of local conditions and regulations.
Literature
1.
Bartenstein P, Asenbaum S, Catafau A, et al. European Association of Nuclear Medicine procedure guidelines for brain imaging using [(18)F]FDG. Eur J Nucl Med Mol Imaging 2002;29:BP43–8.PubMed
2.
Kuwert T, Bartenstein P, Grünwald F, et al. Clinical value of positron emission tomography in neuromedicine. Position paper on results of an interdisciplinary consensus conference. Nervenarzt 1989;69:1045–160.CrossRef
3.
4.
Schelbert HR, Hoh CK, Royal HD, et al. Procedure guideline for tumor imaging using fluorine-18-FDG. Society of Nuclear Medicine. J Nucl Med 1998;39:1302–5.PubMed
5.
Society of Nuclear Medicine Brain Imaging Council. Ethical clinical practice of functional brain imaging. J Nucl Med 1996;37:1256–9.
6.
Messa C, Fazio F, Costa DC, Ell PJ. Clinical brain radionuclide imaging. Semin Nucl Med 1995;25:111–43.CrossRefPubMed
7.
Setani K, Schreckenberger M, Sabri O, et al. Comparison of different methods for attenuation correction in brain PET: effect on the calculation of the metabolic rate of glucose. Nuklearmedizin 2000;39:50–5.PubMed
8.
Herholz K, Salmon E, Perani D, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 2002;17:302–16.CrossRefPubMed
9.
Herholz K, Carter SF, Jones M. Positron emission tomography imaging in dementia. Br J Radiol 2007;80:S160–7.CrossRefPubMed
10.
Mosconi L, Tsui WH, Herholz K, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias. J Nucl Med 2008;49:390–8.CrossRefPubMed
11.
Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734–46.CrossRefPubMed
12.
Kaschten B, Stevenaert A, Sadzot B, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998;39:778–85.PubMed
13.
Henry TR, Votaw JR. The role of positron emission tomography with [18F]fluorodeoxyglucose in the evaluation of the epilepsies. Neuroimaging Clin N Am 2004;14:517–35.CrossRefPubMed
14.
Van Paesschen W, Dupont P, Sunaert S, Goffin K, Van Laere K. The use of SPECT and PET in routine clinical practice in epilepsy. Curr Opin Neurol 2007;20:194–202.CrossRefPubMed
15.
Eckert T, Barnes A, Dhawan V, Frucht S, Gordon MF, Feigin AS, et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 2005;26:912–21.CrossRefPubMed
16.
Eckert T, Tang C, Ma Y, Brown N, Lin T, Frucht S, et al. Abnormal metabolic networks in atypical parkinsonism. Mov Disord 2008;5:727–33.CrossRef
17.
Hasselbalch SG, Knudsen GM, Videbaek C, et al. No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. Diabetes 1999;48:1915–21.CrossRefPubMed
18.
Cranston I, Marsden P, Matyka K, et al. Regional differences in cerebral blood flow and glucose utilization in diabetic man: the effect of insulin. J Cereb Blood Flow Metab 1998;18:130–40.CrossRefPubMed
19.
Spanaki MV, Siegel H, Kopylev L, et al. The effect of vigabatrin (gamma-vinyl GabA) on cerebral blood flow and metabolism. Neurology 1999;53:1518–22.PubMed
20.
Berding G, Odin P, Brooks DJ, et al. Resting regional cerebral glucose metabolism in advanced Parkinson´s disease studied in the off and on conditions with [18F]FDG-PET. Mov Disord 2001;6:1014–22.CrossRef
21.
Felgin A, Fukuda M, Dhawan V, et al. Metabolic correlates of levodopa response in Parkinson´s disease. Neurology 2001;57:2083–8.
22.
Ruotsalainen U, Suhonen-Polvi H, Eronen E, et al. Estimated radiation dose to the newborn in FDG-PET studies. J Nucl Med 1996;37:387–93.PubMed
23.
Wu T-H, Huang Y-H, Lee JJS, Wang S-Y, Wang S-C, Su C-T, et al. Radiation exposure during transmission measurements: comparison between CT- and germanium-based techniques with a current PET scanner. Eur J Nucl Med Mol Imaging 2004;31:38–43.CrossRefPubMed
24.
Chen WP, Matsunari I, Noda A, et al. Rapid scanning protocol for brain (18)F-FDG PET: a validation study. J Nucl Med 2005;46:1633–41.PubMed
25.
Lucignani G, Schmidt KC, Moresco RM, et al. Measurement of regional cerebral glucose utilization with fluorine-18-FDG and PET in heterogeneous tissue: theoretical considerations and practical procedure. J Nucl Med 1993;34:360–9.PubMed
26.
Phelps ME. PET: the merging of biology and imaging into molecular imaging. J Nucl Med 2000;41:661–81.PubMed
27.
Henry TR, Engel J Jr, Mazziotta JC. Clinical evaluation of interictal fluorine-18-fluordeoxyglucose PET in partial epilepsy. J Nucl Med 1993;34:1892–998.PubMed
28.
Schreckenberger M, Spetzger U, Sabri O, et al. Localisation of motor areas in brain tumour patients: a comparison of preoperative 18-FDG-PET and intraoperative cortical electrostimulation. Eur J Nucl Med 2001;28:1394–403.CrossRefPubMed
29.
Herholz K, Pietrzyk U, Karbe H, et al. Individual metabolic anatomy of repeating words demonstrated by MRI-guided positron emission tomography. Neurosci Lett 1994;182:47–50.CrossRefPubMed
30.
Minoshima S, Koeppe RA, Mintun MA, et al. Automated detection of the intercommissural line for stereotactic localization of functional brain images. J Nucl Med 1993;34:322–9.PubMed
31.
Graham MM, Muzi M, Spence AM, et al. The FDG lumped constant in normal human brain. J Nucl Med 2002;43:1157–66.PubMed
32.
Minoshima S, Frey KA, Koeppe RA, et al. A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995;36:1238–48.PubMed
33.
Frackowiak RSJ, Friston KJ, Frith CD, Dolan RJ, Mazziotta JC. Human brain function. London: Academic Press; 1997.
34.
Drzezga A, Arnold S, Minoshima S, et al. F-18 FDG-PET studies in patients with extratemporal and temporal epilepsy: evaluation of an observer-independent analysis. J Nucl Med 1999;40:737–46.PubMed
35.
Cook GJ, Maisey MN, Fogelman I. Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med 1999;26:1363–78.CrossRefPubMed
Metadata
Title
EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2
Authors
Andrea Varrone
Susanne Asenbaum
Thierry Vander Borght
Jan Booij
Flavio Nobili
Kjell Någren
Jacques Darcourt
Özlem L. Kapucu
Klaus Tatsch
Peter Bartenstein
Koen Van Laere
Publication date
01-12-2009
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 12/2009
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-009-1264-0

Other articles of this Issue 12/2009

European Journal of Nuclear Medicine and Molecular Imaging 12/2009 Go to the issue

Original Article

Noninvasive quantification of 18F-FLT human brain PET for the assessment of tumour proliferation in patients with high-grade glioma

Original Article

Tumor delivery of antisense oligomer using trastuzumab within a streptavidin nanoparticle

Guidelines

EANM procedure guideline for brain perfusion SPECT using 99mTc-labelled radiopharmaceuticals, version 2

Original Article

68Ga-DOTA-RGD peptide: biodistribution and binding into atherosclerotic plaques in mice

Original Article

Cardiovascular events in Japanese asymptomatic patients with type 2 diabetes: a 1-year interim report of a J-ACCESS 2 investigation using myocardial perfusion imaging

Image of the Month

Tumoural denervation of the nigrostriatal pathway